All In Biotech

Drug Trial Radar · NCT07502417

A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants

A Phase 1 Study to Assess the Effect of Multiple Doses of ABBV-722 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel

Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

Mar 27, 2026

Primary completion

Jul 2, 2026

Study completion Jul 2, 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Mar 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the effect of repeated doses of ABBV-722 on the single dose pharmacokinetics (PK) of ethinyl estradiol and levonorgestrel.

Conditions

  • Healthy Volunteer

Interventions

  • Ethinyl Estradiol + LevonorgestrelDrug

    Oral

  • ABBV-722Drug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax) of Ethinyl Estradiol and LevonorgestrelTime frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2
  2. Time to Cmax (Tmax) of Ethinyl Estradiol and LevonorgestrelTime frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2
  3. Terminal Phase Elimination Rate Constant (β) of Ethinyl Estradiol and LevonorgestrelTime frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2
  4. Terminal Phase Elimination Half-Life (t1/2) of Ethinyl Estradiol and LevonorgestrelTime frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2
  5. Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUCt) of Ethinyl Estradiol and LevonorgestrelTime frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2
  6. Area Under the Plasma Concentration-Time Curve From Time 0 to Infinite Time (AUCinf) of Ethinyl Estradiol and LevonorgestrelTime frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2
  7. Number of Participants with Adverse Events (AEs)Time frame: Up to Approximately 82 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Acpru /Id# 281745

    Grayslake, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.